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The recognition that variant Creutzfeldt–Jakob disease (vCJD) is caused by the same prion strain as bovine spongiform encephalopathy in
cattle has dramatically highlighted the need for a precise understanding of the molecular biology of human prion diseases. Detailed clinical,
pathological and molecular data from a large number of human prion disease patients indicate that phenotypic diversity in human prion disease
relates in part to the propagation of disease-related PrP isoforms with distinct physicochemical properties. Incubation periods of prion infection in
humans can exceed 50 years and therefore it will be some years before the extent of any human vCJD epidemic can be predicted with confidence.
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Prion diseases are fatal neurodegenerative disorders that
include Creutzfeldt–Jakob disease (CJD), Gerstmann–Sträuss-
ler–Scheinker disease (GSS), fatal familial insomnia (FFI), kuru
and variant CJD (vCJD) in humans [1,2]. Their central feature is
the post-translational conversion of host-encoded, cellular prion
protein (PrPC), to an abnormal isoform, designated PrPSc [1,2].
This transition appears to involve only conformational change
rather than covalent modification and confers PrPSc with partial
resistance to proteolytic degradation and detergent insolubility.
Human prion diseases are biologically unique in that the disease
process can be triggered through inherited germline mutations
in the human prion protein gene (PRNP), infection (by
inoculation, or in some cases by dietary exposure) with prion-
infected tissue or by rare sporadic events that generate PrPSc [2–
4]. Substantial evidence indicates that an abnormal PrP isoform
is the principal, if not the sole, component of the transmissible
infectious agent, or prion [1,2,5,6]. The mechanism of
neurodegeneration that accompanies the accumulation of
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mechanism involving inhibition of the proteosome [8]. The
existence of multiple strains or isolates of prions has been
difficult to accommodate within a protein-only model of prion
propagation and understanding how a protein-only infectious
agent can encode distinct disease phenotypes in humans has
been of considerable biological interest. A wealth of experi-
mental evidence now suggests that prion strain diversity is
encoded within PrP itself and phenotypic diversity in human
prion diseases relates to differing physicochemical properties of
abnormal PrP isoforms [9–18].
2. Aetiology and clinical features of human prion diseases
Human prion diseases can be divided aetiologically into
inherited, sporadic and acquired forms [1,2]. Human prion
diseases with distinct aetiologies are associated with a range of
clinical presentations which are now seen as clinico-pathologi-
cal syndromes rather than individual disease entities [3,4,19].
3. Sporadic CJD
Approximately 85% of cases of human prion disease occur
sporadically as Creutzfeldt–Jakob disease (sporadic CJD) at a
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world, with an equal incidence in men and women [20,21].
The aetiology of sporadic CJD is unknown, although
hypotheses include somatic PRNP mutation [20,22,23], or
the spontaneous conversion of PrPC into PrPSc as a rare
stochastic event [22]. Polymorphism at residue 129 of human
PrP (encoding either methionine (M) or valine (V)) powerfully
affects susceptibility to human prion diseases [21,24–28].
About 38% of Europeans are homozygous for the more
frequent methionine allele, 51% are heterozygous, and 11%
homozygous for valine. Homozygosity at PRNP codon 129
predisposes to the development of sporadic and acquired CJD
[21,24–28]. Most sporadic CJD occurs in individuals homo-
zygous for this polymorphism. This susceptibility factor is also
relevant in the acquired forms of CJD, most strikingly in
vCJD; all clinical cases studied so far have been homozygous
for codon 129 methionine of PRNP (see below). Additionally,
a PRNP susceptibility haplotype has been identified indicating
additional genetic susceptibility to sporadic CJD at or near to
the PRNP locus [29,30].
Classical sporadic CJD presents as a rapidly progressive
multifocal dementia usually with myoclonus. The onset is
usually in the 45–75 years age group with median age at
death of 68 years [21]. The clinical progression is typically
over weeks progressing to akinetic mutism with a median
disease duration of 5 months [21]. Prodromal features,
present in around a third of cases, include fatigue, insomnia,
depression, weight loss, headaches, general malaise and ill-
defined pain sensations. In addition to mental deterioration
and myoclonus, frequent additional neurological features
include extrapyramidal signs, cerebellar ataxia, pyramidal
signs and cortical blindness. Raised cerebrospinal fluid 14-3-
3 protein, neuronal specific enolase (NSE), and S-100,
although not specific for CJD, may be helpful diagnostically
in the appropriate clinical context [21,31–36]. The electro-
encephalogram (EEG) may show characteristic pseudoper-
iodic sharp wave activity that is helpful in diagnosis but
present only in around 60% of cases [21]. In contrast cortical
signal changes on diffusion weighted MRI are extremely
helpful in the diagnosis of CJD [37–42]. Neuropathological
confirmation of CJD is by demonstration of spongiform
change, neuronal loss and astrocytosis. PrP amyloid plaques
are usually not present in CJD [43] although PrP
immunohistochemistry, is nearly always positive [43–45].
Atypical forms of sporadic CJD are well recognised. 10%
of cases of CJD have a much more prolonged clinical course
with a disease duration of over 2 years [46]. Around 10% of
CJD cases present with cerebellar ataxia rather than cognitive
impairment, so-called ataxic CJD [47]. Heidenhain's variant
of CJD refers to cases in which cortical blindness
predominates with severe involvement of the occipital
lobes. The panencephalopathic type of CJD refers to cases
with extensive degeneration of the cerebral white matter in
addition to spongiform vacuolation of the gray matter and
has been predominately reported from Japan [47–49].
Amyotrophic variants of CJD have been described with
prominent early muscle wasting. However, most cases ofdementia with amyotrophy are not experimentally transmis-
sible and their relationship with CJD is unclear [50,51].
4. Inherited prion disease
Approximately 15% of human prion diseases are asso-
ciated with autosomal dominant pathogenic mutations in
PRNP [14,22,52–54]. How pathogenic mutations in PRNP
cause prion disease has yet to be resolved, however, in most
cases the mutation is thought to lead to an increased
tendency of PrPC to form PrPSc, although there is evidence
to suggest that this may not be solely attributable to
decreased thermodynamic stability of mutated PrPC [55,56].
Experimentally manipulated mutations of the prion gene can
lead to spontaneous neurodegeneration without the formation
of detectable protease resistant PrP [57,58]. These findings
raise the question of whether all inherited forms of human
prion disease invoke disease through the same mechanism,
and in this regard it is currently unknown whether all are
transmissible by inoculation [52].
Over 30 autosomal dominant pathogenic PRNP mutations
have been described [2,3,53,54]. In the appropriate clinical
setting identification of a pathogenic PRNP mutation provides
diagnosis of inherited prion disease and sub-classification
according to mutation; PRNP analysis is also used for pre-
symptomatic genetic testing in affected families [4,52,54,59].
Traditionally, inherited prion diseases have been classified by
the presenting clinical syndrome, falling into three main sub-
divisions of either GSS, CJD or FFI. GSS classically presents
as a chronic cerebellar ataxia with pyramidal features with
dementia occurring much later in a clinical course that is
typically longer than that seen in classical CJD [52]. Fatal
familial insomnia (FFI) is characterised by progressive
untreatable insomnia, dysautonmoia and dementia, selective
thalamic degeneration and is most commonly associated with
a missense mutation at codon 178 of PRNP [60], although
sporadic FFI with no causative mutation in PRNP has been
reported [61,62]. Remarkably, some families show extensive
phenotypic variability which can encompass both CJD- and
GSS-like cases as well as other cases which do not conform
to either CJD or GSS phenotypes [19,53,54,63–66]. Progres-
sive dementia, cerebellar ataxia, pyramidal signs, chorea,
myoclonus, extrapyramidal features, pseudobulbar signs,
seizures and amyotrophic features can be seen in variable
combinations. Such atypical prion diseases may lack the
classical histological features of a spongiform encephalopathy
entirely although PrP immunohistochemistry is usually
positive [64]. The existence of phenotypic overlap between
individuals with different mutations and even in family
members with the same PRNP mutation indicates that ac-
curate classification of inherited human prion diseases should
be based upon mutation alone [19,67]. Because of the
extensive phenotypic variability seen in inherited prion
disease and its ability to mimic other neurodegenerative con-
ditions, notably Alzheimer's disease, PRNP analysis should
be considered in all patients with undiagnosed dementing and
ataxic disorders [19,63,64,68].
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Although the human prion diseases are transmissible
diseases, acquired forms have, until recently, been confined to
rare and unusual situations.
5.1. Iatrogenic CJD
The two most frequent causes of iatrogenic CJD occurring
through medical procedures have arisen as a result of
implantation of dura mater grafts and treatment with growth
hormone derived from the pituitary glands of human cadavers
[69,70]. Less frequent incidences of human prion disease have
resulted from iatrogenic transmission of CJD during corneal
transplantation, contaminated electroencephalographic (EEG)
electrode implantation and surgical operations using contami-
nated instruments or apparatus [69,70]. The clinical presenta-
tion in iatrogenic forms of human prion disease appear to be
related to their aetiology and in particular the route of exposure
to human prions [52,70,71]. Peripheral routes of infection are
typically associated with longer incubation periods and usually
present with a kuru-like syndrome in which ataxia rather than
dementia is the prominent early clinical feature. In contrast,
patients with dura mater graft-related exposure to human prions,
in which infectivity is placed in closed proximity to the brain,
typically have a clinical presentation similar to that of sporadic
CJD [72], although exceptions with unusual clinical features
have been reported [73].
5.2. Kuru
The most well-known example of acquired prion disease in
humans is kuru, transmitted by cannibalism among the Fore
linguistic group of the Eastern Highlands in Papua New Guinea
[28,52,74,75]. The central clinical feature of kuru is progressive
cerebellar ataxia and in sharp contrast to sporadic CJD,
dementia is late and may be absent. A prodrome and three
clinical stages consisting of an ambulatory stage, a sedentary
stage and a tertiary stage have been described [52,74,75].
Remarkably, kuru demonstrates that incubation periods of
infection with human prions can exceed 50 years [75]. PRNP
codon 129 genotype has shown a pronounced effect on kuru
incubation periods and susceptibility, and most elderly
survivors of the kuru epidemic are heterozygotes [27,28,75].
The clear survival advantage for codon 129 heterozygotes
provides a powerful basis for selection pressure in the Fore
[28,75]. However, an analysis of worldwide haplotype diversity
and allele frequency of coding and non-coding polymorphisms
of PRNP suggests that balancing selection at this locus (in
which there is more variation than expected because of
heterozygote advantage) is much older and more geographically
widespread [28]. Evidence for balancing selection has been
shown in only a few human genes. With biochemical and
physical evidence of cannibalism on five continents, one
explanation is that cannibalism resulted in prion disease
epidemics in human prehistory, thus imposing balancing
selection on PRNP [28].5.3. Variant CJD
The appearance of a novel human prion disease, variant CJD
(vCJD), in the United Kingdom from 1995 onwards [76], and
the experimental confirmation that this is caused by the same
prion strain as that causing BSE in cattle [10,77–79], has led to
widespread concern that exposure to the epidemic of BSE poses
a distinct and conceivably a severe threat to public health in the
United Kingdom and other countries [4,80]. The extremely
prolonged and variable incubation periods seen with prion
diseases when crossing a species barrier means that it will be
some years before the parameters of any human epidemic can be
predicted with confidence [75,80–83]. In the meantime, we are
faced with the possibility that significant numbers in the
population may be incubating this disease and that they might
pass it on to others via blood transfusion, blood products, tissue
and organ transplantation and other iatrogenic routes [80,84–
87].
To date, the clinical presentation of human BSE infection has
only been recognised as vCJD in PRNP codon 129 methionine
homozygotes. The neuropathological features of vCJD are
somewhat different from those seen in classical (sporadic or
iatrogenic) CJD, and are characterised by the presence of
abundant florid PrP plaques [76,88] and the propagation of type
4 PrPSc in brain [10,15] (Fig. 1). The early clinical presentation
of vCJD resembles kuru more than classical CJD and consists of
behavioral and psychiatric disturbances, peripheral sensory
disturbance and cerebellar ataxia. Common early psychiatric
features include depression, withdrawal, anxiety, insomnia, and
apathy. Neurological symptoms have preceded psychiatric
symptoms in a minority of cases. No common early
neurological features have been reported, but paraesthesiae
and/or pain in the limbs is seen in around half of the cases.
However a significant proportion of patients exhibited neuro-
logical symptoms within 4 months of clinical onset, and these
included poor memory, pain, sensory symptoms, unsteadiness
of gait and dysarthia. Disorientation, hallucinations, paranoid
ideation, confabulation, impaired self-care, and the commonest
neurological features (cerebellar signs, chorea, dystonia,
myoclonus, upper motor neuron signs and visual symptoms),
develop late in the course of the illness [89]. The duration of
disease is longer in vCJD with mean patient survival times of
about 14 months [36], compared with about 5 months for
classical CJD [21]. Moreover, whereas classical CJD is
predominantly a late onset disease with a median age at death
of 68 years [21], the median age of onset of vCJD is 26 years
[36,89]. The EEG is not helpful in the diagnosis of vCJD, whilst
generalised slowing is usually present, the characteristic
periodic changes associated with classical CJD are not. The
CSF 14-3-3 protein is not helpful, and may often be negative
[90]. The most useful non-invasive investigation in advanced
cases of vCJD has been MR neuroimaging, particularly the
FLAIR sequence [91]. Early case reports noted bilateral
increased signal in the posterior thalamus (pulvinar) on T2
weighted images [92]. A retrospective review of MR scans from
36 histologically confirmed cases of vCJD using mainly other
forms of human prion disease subjects as controls suggested
Fig. 1. Characterisation of disease related prion protein in human prion disease.
(A) Immunoblots of proteinase K digested tissue homogenate with anti-PrP
monoclonal antibody 3F4 showing PrPSc types 1–4 in human brain and PrPSc
type 4t in vCJD tonsil. Types 1–3 PrPSc are seen in the brain of classical forms of
CJD (either sporadic or iatrogenic CJD), while type 4 PrPSc and type 4t PrPSc are
uniquely seen in vCJD brain or tonsil, respectively. (B, C) Brain from patients
with sporadic CJD or vCJD show abnormal PrP immunoreactivity following
immunohistochemistry using anti-PrP monoclonal antibody ICSM35. Abnormal
PrP deposition in sporadic CJD brain most commonly presents as diffuse,
synaptic staining, whereas vCJD brain is distinguished by the presence of florid
PrP plaques consisting of a round amyloid core of PrP surrounded by a ring of
spongiform vacuoles. Scale bars B and C, 50 μm.
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of vCJD [93]. However, histologically confirmed cases of vCJD
with minimal or absent pulvinar changes on MR neuroimaging
at a mean 10.5 months during an illness of mean 15 months
duration were identified in this series. The absence of
characteristic MR findings does therefore not exclude a
diagnosis of vCJD and more recently figures of 81% sensitivity
and 94% specificity have been reported in a series of patients
including 27 cases of vCJD diagnosed by tonsil biopsy [94]. Asthese studies suggest, the pulvinar sign is not specific for vCJD
and these MRI appearances are described in sporadic CJD [95],
paraneoplastic limbic encephalitis [96] and in a number of rare
conditions [97–100]. In contrast, a firm tissue based diagnosis
of vCJD can be made during life by tonsil biopsy, with
demonstration of a characteristic sub-type of PrPSc (see below).
6. Molecular basis of phenotypic variability in human prion
disease
The marked clinical heterogeneity observed in human prion
diseases has yet to be explained. However, it has been clear for
many years that distinct isolates, or strains, of prions can be
propagated in the same host and these are biologically recognised
by distinctive clinical and pathological features [2,101,102]. It is
therefore likely that a proportion of clinicopathological hetero-
geneity seen in sporadic CJD and other human prion diseases
relates to the propagation of distinct human prion strains. Within
the framework of the protein-only hypothesis of prion propaga-
tion, distinct clinical and neuropathological phenotypes are
thought to be determined by the propagation of distinct PrPSc
isoforms with divergent physicochemical properties [1,2,9–
11,103,104]. Furthermore the propagation of distinct abnor-
mal PrP isoforms may be determined by the host genome
[79,105,106].
To date we have identified four major types of human PrPSc
associated with sporadic and acquired human prion diseases that
can be differentiated on immunoblots after limited proteinase K
digestion of brain homogenates [10,12,15] (Fig. 1). PrPSc types
1–3 are seen in classical (sporadic or iatrogenic) CJD brain,
while type 4 PrPSc is uniquely seen in vCJD brain [10,12,15].
An earlier classification of PrPSc types seen in classical CJD
described only two banding patterns [11] with PrPSc types 1 and
2 that we describe corresponding with the type 1 pattern of
Gambetti and colleagues, and our type 3 fragment size
corresponding to their type 2 pattern [13,107]. While type 4
PrPSc is readily distinguished from the PrPSc types seen in
classical CJD by a predominance of the di-glycosylated PrP
glycoform, type 4 PrPSc also has a distinct proteolytic fragment
size [15] although this is not recognised by the alternative
classification which designates type 4 PrPSc as type 2b [107].
In addition to the identification of distinct human PrPSc
types associated with sporadic and acquired prion disease,
molecular strain typing has provided insights into the
phenotypic heterogeneity seen in inherited human prion
diseases [53,108]. In agreement with existing evidence that
human prion strain diversity is generated through variance in
PrPSc conformation and glycosylation, cases of inherited prion
disease caused by point mutations have glycoform ratios of
PrPSc fragments distinct from those seen in both classical CJD
[108–112] and vCJD [108]. Individuals with the same PRNP
mutation can also propagate PrPSc with distinct fragment sizes
[108,109,113]. Notably however the detection of PrPSc in the
molecular mass range of ca. 21–30 kDa is by no means a con-
sistent feature. Instead, some cases, in particular those in which
amyloid plaques are a prominent feature, show smaller protease
resistant fragments of ca. 7–15 kDa [53,108–110,113,114]. The
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make a significant contribution to phenotypic variability in
inherited prion disease [23,115–117]. These collective data
indicate that PrPSc isoforms may be generated in inherited
prion disease with unique physicochemical properties, reflected
by sensitivity to proteinase K digestion or PrPSc/prion
infectivity ratios that are very different from the PrPSc types
propagated in sporadic and acquired forms of human prion
disease. For example in P102L inherited prion disease, it is
now apparent that three isoforms of protease resistant PrP with
divergent physicochemical properties can be propagated. Two
distinct abnormal conformers derived from PrP 102L generate
protease-resistant fragments of either ca. 21–30 kDa or 8 kDa
[23,108–110,118], while abnormal conformers of wild type
PrP appear to generate proteolytic fragments of only ca. 21–
30 kDa [23]. Glycoform ratios of ca. 21–30 kDa proteolytic
fragments generated from PrP 102L and wild type PrP are not
only distinct from each other, but are also distinct from those
generated from wild type PrP in sporadic or acquired CJD [23].
Differences in neuropathological targeting of these distinct
disease-related PrP species, together with differences in their
abundance and potential neurotoxicity, provides a molecular
mechanism for generation of multiple phenotypes in P102L
inherited prion disease. Clearly, new experimental methods
may be required in order to fully document the spectrum of
abnormal PrP isoforms seen in inherited prion disease. In this
context it is important to note that not all inherited prion disease
may invoke disease through the same mechanism. For example
the PRNP A117V mutation gives rise to transmembrane forms
of PrP (PrPctm) which it is proposed may invoke a neurological
disease without generation of PrPSc [58]. It is also not presently
known whether all inherited prion diseases are transmissible by
inoculation.
Efforts to produce an unified international classification and
nomenclature of human PrPSc types has been complicated by
the fact that the N-terminal conformation of some PrPSc
subtypes seen in sporadic CJD can be altered in vitro via
changes in metal-ion occupancy [12,15] or solvent pH [119–
121]. Additionally there is now increasing evidence for co-
existence of different PrPSc types within the same brain
[13,15,21,23,108–110,122–127]. While it has recently been
proposed that pH alone determines the N-terminal structure of
PrPSc in sporadic CJD [120,121], this interpretation has not
been supported by other studies [12,17,124], and specific PrPSc
conformations show critical dependence upon the presence of
copper or zinc ions under conditions where pH 7.4 is strictly
controlled [12]. Although agreement has yet to be reached on
methodological differences, nomenclature and the biological
importance of relatively subtle biochemical differences in
PrPSc, there is strong agreement between laboratories that
phenotypic diversity in human prion disease relates in
significant part to the propagation of disease-related PrP
isoforms with distinct physicochemical properties [9–
18,124,127,128]. Importantly, it is now also becoming apparent
that protease-sensitive pathological isoforms of PrP may have a
significant role in both animal and human prion disease
[18,104,129,130] and therefore development of new diagnostictests that do not rely on protease digestion are required. In this
context, the conformation-dependent immunoassay [104] has
recently been reported to have high diagnostic sensitivity in
human prion disease [18].
The hypothesis that alternative conformations or assembly
states of PrP provide the molecular substrate for clinicopatho-
logical heterogeneity seen in human prion diseases (and that this
relates to the existence of distinct human prion strains) has been
strongly supported by transmission experiments to conventional
and transgenic mice. Transgenic mice expressing only human
PrP with either valine (V) or methionine (M) at residue 129 have
shown that this polymorphism constrains both the propagation
of distinct human PrPSc conformers and the occurrence of
associated patterns of neuropathology [10,77,79,131,132].
Biophysical measurements suggest that this powerful effect of
residue 129 on prion strain selection is likely to be mediated via
its effect on the conformation of PrPSc or its precursors or on the
kinetics of their formation, as it has no measurable effect on the
folding, dynamics or stability of PrPC [133]. These data are
consistent with a conformational selection model of prion
transmission barriers [2,80,131,134] (a model also recently
supported by work with yeast prions [135]) and strongly support
the “protein only” hypothesis of infectivity by suggesting that
prion strain variation is encoded by a combination of PrP
conformation and glycosylation [2]. These findings also provide
a molecular basis for PRNP codon 129 as a major locus in-
fluencing both prion disease susceptibility and phenotype in
humans.
Notably, our transgenic modeling studies indicate that there
is no common preferred PrPSc conformation for V129 and
M129 human PrP that can be generated as a result of exposure
to the vCJD/BSE prion strain [131]. Depending on the origin of
the inoculum and the PrP codon 129 genotype of the host,
primary or secondary transmission of BSE-derived prions can
result in four distinct prion disease phenotypes. Transgenic mice
homozygous for human PrP M129 propagate either type 2 or 4
PrPSc with respective neuropathologies consistent with human
sporadic CJD or vCJD [79,131], whereas transgenic mice
homozygous for human PrP V129 either propagate type 5 PrPSc
and a distinct pattern of neuropathology, or develop clinical
prion disease in the absence of detectable PrPSc [77,131].
Depending on the source of the inoculum, multiple disease
phenotypes are also seen in human PrP codon 129MV
heterozygous transgenic mice [132]. However in the PrP
codon 129MV genotype, none of these phenotypes resemble
the neuropathological phenotype of vCJD as the propagation of
type 4 PrPSc is dissociated from the occurrence of abundant
florid PrP plaques [132]. While caution must be exercised in
extrapolating from animal models, even where faithful
recapitulation of molecular and pathological phenotypes is
possible [79,131] (Fig. 2), our data, together with closely
similar findings of Manson and colleagues [136], argue that
primary human BSE prion infection, and secondary infection
with vCJD prions by iatrogenic routes, may not be restricted to a
single disease phenotype. Stratification of all human prion
disease cases by PrPSc type will enable rapid recognition of any
change in relative frequencies of particular PrPSc sub-types in
Fig. 2. Recapitulation of vCJD molecular and neuropathological phenotype in transgenic mice. Primary transmission of vCJD prions to transgenic Tg
(HuPrP129M+/+Prnpo/o)-35 mice (Tg35) results in faithful propagation of type 4 PrPSc and the occurrence of abundant florid PrP plaques that are the neuropathological
hallmark of vCJD. In contrast, primary transmission of vCJD prions to transgenic Tg(HuPrP129V+/+Prnpo/o)-152 mice (Tg152) produces type 5 PrPSc and a distinct
pattern of neuropathology that is maintained after secondary passage in Tg152 mice but after passage in Tg35 mice induces propagation of either type 4 or type 2 PrPSc
and respective neuropathologies consistent with vCJD or sporadic CJD. (A) Representative immuno-blots of proteinase-K treated brain homogenates from variant and
sporadic CJD (PRNP 129 MM genotype) and transgenic mice analysed with anti-PrP monoclonal antibody 3F4. The identity of the brain sample is designated above
each lane with the type of PrPSc present in the sample designated below. (B) Representative immunohistochemical analysis of transgenic mouse brain showing
abnormal PrP immunoreactivity, including PrP-positive plaques, stained with anti-PrP monoclonal antibody 3F4. Scale bar: 100 μm. Lower panels show the regional
distribution of abnormal PrP deposition. Green boxes in the sketches denote the area from which PrP stained sections are derived.
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vCJD prions [2,79,131,132].
7. Peripheral pathogenesis in human prion disease
Concomitant with studies on PrPSc from brain has been
investigation of PrPSc in peripheral tissues in human prion
diseases. These studies have established that the pathogenesis of
vCJD differs significantly from that of other forms of CJD.
PrPSc is readily detectable in lymphoreticular tissues in vCJD
and not in classical CJD or inherited prion disease [84,108,137–142]. The fact that tonsillar prion infection has not been
detected in iatrogenic CJD associated with use of human
cadaveric derived pituitary hormone [138] or kuru (our
unpublished data) argues that the distinctive pathogenesis of
vCJD relates to the effect of prion strain rather than to a
peripheral route of infection.
Depending upon the density of lymphoid follicles, PrPSc
concentrations in vCJD peripheral tissues can vary enormously,
with levels relative to brain as high as 10% in tonsil [84,138] or
as low as 0.002% in rectum [84]. A distinctive PrPSc type,
designated type 4t, is seen in both ante-mortem and post-
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including secondary vCJD infection resulting from blood
transfusion [87]. Type 4t PrPSc in tonsil differs in the
proportions of the PrP glycoforms from type 4 PrPSc seen in
vCJD brain [84,138] implying the superimposition of tissue and
strain specific effects on PrP glycosylation [80,138]. As
infection of lymphoreticular tissues is thought to precede
neuroinvasion, and indeed has been detected in archived
surgical samples removed prior to development of vCJD
[81,143], tonsil biopsy is likely to allow firm diagnosis at the
early clinical stage or indeed pre-clinically [4]. Early diagnosis
obviates the need for further investigation, which may include
brain biopsy, necessary to exclude alternative potentially
treatable conditions and will be increasingly important with
the advent of putative treatments and clinical trials where the
aim must be to intervene early before extensive CNS damage
has occurred [4]. To date tonsil biopsy has shown has shown
100% sensitivity and specificity for diagnosis of clinical vCJD
[84,94,137,138] (and our unpublished data).
The distinctive peripheral pathogenesis of vCJD has
provided the basis for prevalence screening of the general
population for vCJD infection. Two anonymous screens of
lymphoreticular tissues, removed during routine surgery, have
been performed [81,82]. Tonsil appears a more sensitive
reporter of vCJD prion infection than appendix [144] and it is
of concern that three positives appendix specimens were
reported from a retrospective screen of around 12 000 largely
appendix samples [81]. A pilot scale prospective study of 2000
tonsils found no positives, despite use of high sensitivity
methods [82]. However, this negative result cannot provide
reassurance that significant community infection is unlikely
because of the relatively small sample size, demographic and
age-related factors and unknown test sensitivity during the
prolonged incubation period [82]. Accordingly, a national large
scale study is now being organized by the UK Department of
Health which aims to screen 100,000 tonsils for disease-
associated PrP to estimate prevalence of vCJD prion infection in
the UK population.
8. Secondary transmission of vCJD prions
The unknown but potentially high prevalence of clinically
silent infection with BSE prions allied with the distinctive
pathogenesis of vCJD has led to significant concerns that there
may be substantial risks of iatrogenic transmission of vCJD
prions via blood products and contaminated surgical and
medical instruments [80,84,142,145].
Indeed three cases of transfusion-associated vCJD prion
infection have already been reported from amongst a very small
cohort of known exposed individuals [85–87]. Prions resist
many conventional sterilisation procedures and surgical stain-
less steel-bound prions transmit disease with remarkable
efficiency when implanted into mice [146,147].
Precautionary risk reduction measures have already been
taken with respect to blood and blood products [85,148]
however major concerns remain relating to possible iatrogenic
transmission of vCJD prions via contaminated surgical instru-ments. Transmission of vCJD to conventional mice involves a
transmission barrier that severely limits the ability to detect low
titre infectivity [77–79,149]. Pending development of a
transmission barrier-free model for bioassay of vCJD prions,
high sensitivity immunodetection of PrPSc has been used to
provide an upper limit on PrPSc levels in peripheral tissues,
including blood, to inform risk assessment models [84,141,142].
High concentrations of PrPSc appear to be largely confined to the
central nervous system and lymphoreticular tissues in vCJD.
While a range of surgically important tissues have levels of PrPSc
104–105 fold lower than found in brain [84], the demonstration
of prion infectivity in vCJD rectum despite barely detectable
levels of PrPSc is consistent with PrPSc/prion infectivity ratios in
vCJD being closely similar to experimental rodent prion strains
[145]. These findings strongly endorse the value of PrPSc
analysis in vCJD for defining risk reduction strategies to limit
secondary transmission of vCJD prions and reinforce concerns
that iatrogenic transmission of vCJD prions might occur through
contaminated endoscopes, biopsy forceps or surgical instru-
ments [142,145,147,150,151].
Predictions of the eventual size of a vCJD epidemic have
varied widely, although some recent estimates, based on current
cases of vCJD, suggest that the total epidemic may be relatively
small [152]. However, key uncertainties, notably with respect to
major genetic effects on the incubation period [54,105], suggest
the need for caution. Importantly, such models cannot estimate
the number of infected individuals, which remains unknown.
The mean incubation period for kuru has been estimated to be
around 12 years [75] with a similar estimate in iatrogenic CJD
associated with the use of human-cadaver-derived pituitary
growth hormone [70]. However, the maximum incubation
periods in kuru can exceed 50 years [75]. The transmission
barrier of BSE between cattle and human beings is unknown
and cannot be directly measured. However, the cattle-to-mouse
barrier for BSE has been well characterised experimentally by
comparative endpoint titration. BSE prions transmit readily to
laboratory mice, including after oral dosing [153]. The murine
LD50 (lethal dose causing 50% mortality) in C57Bl/6 mice is
about 500-fold higher than that in cattle [154]; this barrier also
results in a three-fold to four-fold increase in mean incubation
period. Mean incubation periods of human BSE infection of
30 years or more should therefore be regarded as possible, if not
probable, with the longest incubation periods approaching (and
perhaps exceeding) the typical human lifespan [75]. The mean
incubation periods of secondary vCJD (involving human-to-
human transmission) would however be expected to have
considerably shorter mean incubation periods than in primary
vCJD resulting from exposure to BSE prions. The incubation
periods seen in the first clinical cases of secondary vCJD are 6
and 6.5 years [85,87] suggesting the shortest incubation periods
of primary vCJD will be much longer, particularly as the oral
route of transmission is also typically associated with longer
incubation periods than parenteral routes. A preliminary
estimate of the shortest incubation periods of primary vCJD,
based on the youngest cases seen, is around 12 years which
would be consistent with such extrapolation from the shortest
incubation periods in secondary vCJD [75].
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129 genotypes, VV and MV, will also succumb to clinical
disease with longer mean incubation periods after primary
infection with BSE prions or secondary transmission of vCJD
prions. The PRNP 129MV blood transfusion recipient had
evidence of prion infection of lymphoreticular tissues at
autopsy but died from a ruptured abdominal aortic aneurysm
with no reported evidence of a neurological disorder; the brain
showed no pathological features of vCJD [86]. It is unclear if
this individual would have gone on to develop clinical prion
disease had they lived longer and if so would have had the
phenotype of vCJD. Subclinical or carrier states of prion
infection are recognised in animal models [134,155], including
BSE or vCJD prion-inoculated transgenic mice expressing
human prion proteins [79,131,132,136]. Modelling suscept-
ibility in such “humanised” transgenic mice suggests such
genotypes will be susceptible but may develop disease
phenotypes distinct from vCJD because of selection and
propagation of different prion strain types [131,132]. The
absence of detectable brain PrPSc in the 129 MV blood
transfusion patient precluded molecular strain typing of prions.
Although splenic PrPSc from this case resembled that seen in
vCJD, this required use of phosphotungstic acid precipitation
of PrPSc which interferes with molecular strain typing [84]. In
addition, type 5 PrPSc, seen in vCJD-inoculated transgenic
mice expressing human PrP 129V, but not yet documented in
humans, has a similar glycoform profile [77,131,132]. It is
possible that this patient was propagating a prion strain distinct
from that causing vCJD. Importantly, Peden et al. noted that
they were unable to detect PrPSc in lymphoid follicles in tonsil,
appendix or large intestine from this patient, although abnormal
PrP was detected in spleen and in a cervical lymph node. As
tonsillar involvement has to date been invariably seen in
clinically affected cases of vCJD, Peden et al. speculated that
this case may represent a distinctive pathogenesis related to
route of exposure (intravenous rather than the oral route of
exposure to BSE prions presumed in primary vCJD). It is also
possible that the absence of a species barrier in secondary
(human to human) infection may affect phenotype. However
the detection of type 4t PrPSc in the tonsil of the most recent
codon 129MM transfusion case [87] argues against these
interpretations, and suggests that absence of tonsillar PrPSc in
the MV blood recipient may be due to the effect of PRNP
genotype and perhaps selection of a distinctive prion strain.
These findings highlight the importance of the need for
continued surveillance and investigation of all forms of human
prion disease within the UK and other populations with
extensive dietary exposure to BSE prions.
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